Denali Therapeutics' (DNLI) Buy Rating Reaffirmed at HC Wainwright

Denali Therapeutics (NASDAQ:DNLI - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $95.00 target price on the stock. HC Wainwright's price objective would suggest a potential upside of 402.65% from the company's current price.

Several other brokerages have also commented on DNLI. UBS Group decreased their price objective on shares of Denali Therapeutics from $70.00 to $32.00 and set a "buy" rating for the company in a report on Tuesday, April 9th. Stifel Nicolaus lowered their price objective on shares of Denali Therapeutics from $26.00 to $22.00 and set a "hold" rating for the company in a report on Wednesday. The Goldman Sachs Group reduced their target price on Denali Therapeutics from $73.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, February 29th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $31.00 price target on shares of Denali Therapeutics in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Denali Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $40.22.

Denali Therapeutics Trading Up 12.2 %

Shares of NASDAQ:DNLI traded up $2.05 on Wednesday, reaching $18.90. 2,702,102 shares of the company traded hands, compared to its average volume of 1,180,243. The stock has a market capitalization of $2.69 billion, a P/E ratio of -17.64 and a beta of 1.39. The business's 50-day simple moving average is $18.82 and its 200 day simple moving average is $18.84. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $33.31.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same period in the prior year, the business earned ($0.80) EPS. Sell-side analysts expect that Denali Therapeutics will post -2.61 EPS for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,666 shares of the business's stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $18.37, for a total transaction of $30,604.42. Following the transaction, the director now owns 121,375 shares of the company's stock, valued at approximately $2,229,658.75. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Steve E. Krognes sold 92,500 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the sale, the director now owns 47,341 shares in the company, valued at approximately $970,490.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $18.37, for a total transaction of $30,604.42. Following the transaction, the director now directly owns 121,375 shares of the company's stock, valued at $2,229,658.75. The disclosure for this sale can be found here. Insiders have sold a total of 110,955 shares of company stock worth $2,218,802 over the last ninety days. Company insiders own 7.90% of the company's stock.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC grew its stake in shares of Denali Therapeutics by 216.7% during the fourth quarter. CWM LLC now owns 2,011 shares of the company's stock valued at $43,000 after buying an additional 1,376 shares during the last quarter. Assetmark Inc. increased its stake in Denali Therapeutics by 49.1% in the third quarter. Assetmark Inc. now owns 2,148 shares of the company's stock worth $44,000 after purchasing an additional 707 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Denali Therapeutics by 48.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company's stock worth $53,000 after purchasing an additional 807 shares during the last quarter. Fisher Asset Management LLC purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at $59,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Denali Therapeutics by 96.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company's stock valued at $73,000 after purchasing an additional 1,732 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.